

Jeffrey R Curtis

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6658027/jeffrey-r-curtis-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

317
papers

15,785
citations

57
h-index

118
g-index

338
ext. papers

19,133
ext. citations

4.5
avg, IF

6.57
L-index

#	Paper	IF	Citations
317	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1-26	9.5	1274
316	2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012 , 64, 625-39	4.7	1199
315	American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 762-84		1118
314	The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 2520-6	6.3	905
313	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016 , 68, 1-25	4.7	717
312	Population-based assessment of adverse events associated with long-term glucocorticoid use. <i>Arthritis and Rheumatism</i> , 2006 , 55, 420-6		338
311	Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. <i>Arthritis and Rheumatism</i> , 2007 , 56, 1125-33		301
310	A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2824-35		271
309	Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1253-1262	2.4	257
308	Initiation of tumor necrosis factor- α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 2331-9	27.4	256
307	Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 576-82	2.4	250
306	Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. <i>Journal of Rheumatology</i> , 2014 , 41, 837-52	4.1	223
305	Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1920-5	2.4	213
304	Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 43-9	27.4	205
303	High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 785-91	2.4	190
302	Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. <i>Clinical Therapeutics</i> , 2011 , 33, 679-707	3.5	185
301	Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1843-7	2.4	152

300	Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. <i>Arthritis Research and Therapy</i> , 2019 , 21, 89	5.7	138
299	A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. <i>Seminars in Arthritis and Rheumatism</i> , 2010 , 40, 2-14.e1	5.3	136
298	Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. <i>Arthritis Care and Research</i> , 2012 , 64, 1794-803	4.7	130
297	Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1960-1968	9.5	129
296	Obesity and response to anti-tumor necrosis factor- α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2018 , 13, e0195123	3.7	118
295	Development of a multi-biomarker disease activity test for rheumatoid arthritis. <i>PLoS ONE</i> , 2013 , 8, e60635	3.5	117
294	Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1430-8		107
293	Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 831-41	2.4	105
292	Recent trends in hip fracture rates by race/ethnicity among older US adults. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 2325-32	6.3	102
291	Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. <i>Arthritis and Rheumatology</i> , 2016 , 68, 56-66	9.5	101
290	Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 644-649	2.4	99
289	Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2612-2617	9.5	99
288	The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1301-8	2.4	94
287	Validity of claims-based stroke algorithms in contemporary Medicare data: reasons for geographic and racial differences in stroke (REGARDS) study linked with medicare claims. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014 , 7, 611-9	5.8	93
286	Identification and validation of vertebral compression fractures using administrative claims data. <i>Medical Care</i> , 2009 , 47, 69-72	3.1	93
285	Longitudinal trends in use of bone mass measurement among older americans, 1999-2005. <i>Journal of Bone and Mineral Research</i> , 2008 , 23, 1061-7	6.3	93
284	Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. <i>Journal of Bone and Mineral Research</i> , 2008 , 23, 1435-41	6.3	92
283	Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2328-37	9.5	90

282	Death, debility, and destitution following hip fracture. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014 , 69, 346-53	6.4	89
281	Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. <i>JAMA Dermatology</i> , 2016 , 152, 164-72	5.1	88
280	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1093-1107	9.5	85
279	Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. <i>Arthritis Care and Research</i> , 2015 , 67, 731-6	4.7	82
278	Population-based fracture risk assessment and osteoporosis treatment disparities by race and gender. <i>Journal of General Internal Medicine</i> , 2009 , 24, 956-62	4	80
277	Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAFETY Assessment of Biologic Therapy (SABER) study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1942-8	2.4	77
276	The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1401-6	2.4	77
275	The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. <i>Arthritis Research and Therapy</i> , 2011 , 13, R174	5.7	76
274	Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor agents, a retrospective cohort study. <i>Arthritis Research and Therapy</i> , 2015 , 17, 319	5.7	75
273	Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 43, 489-97	5.3	74
272	Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996-2009. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 842-9	2.6	72
271	Cardiovascular risk in rheumatoid arthritis: comparing TNF-blockade with nonbiologic DMARDs. <i>American Journal of Medicine</i> , 2013 , 126, 730.e9-730.e17	2.4	72
270	Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. <i>Medical Care</i> , 2009 , 47, 334-41	3.1	72
269	2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. <i>Arthritis Care and Research</i> , 2019 , 71, 1540-1555	4.7	71
268	Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial. <i>Archives of Internal Medicine</i> , 2007 , 167, 591-6		70
267	Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1400-1413	2.4	68
266	Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1813-8	2.4	66
265	Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-Directed Therapy for Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2018 , 113, 405-417	0.7	65

264	Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1065-71	2.4	64
263	The incidence of gastrointestinal perforations among rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 2011 , 63, 346-51		63
262	Identifying types of nursing facility stays using medicare claims data: an algorithm and validation. <i>Health Services and Outcomes Research Methodology</i> , 2010 , 10, 100-110	1.6	57
261	Linkage of a de-identified United States rheumatoid arthritis registry with administrative data to facilitate comparative effectiveness research. <i>Arthritis Care and Research</i> , 2014 , 66, 1790-8	4.7	56
260	Bisphosphonate-associated osteonecrosis of the jaw, with healing after teriparatide: a review of the literature and a case report. <i>Special Care in Dentistry</i> , 2010 , 30, 77-82	1.7	56
259	Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users. <i>Pharmacoepidemiology and Drug Safety</i> , 2006 , 15, 710-8	2.6	56
258	Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations. <i>Arthritis and Rheumatism</i> , 2012 , 64, 630-8		55
257	Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs. <i>Arthritis Care and Research</i> , 2015 , 67, 1671-8	4.7	55
256	Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1293-1301.e5; quiz e70, e72	6.9	54
255	Association between anti-TNF- α therapy and interstitial lung disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 394-402	2.6	51
254	Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>Arthritis Care and Research</i> , 2020 , 72, 561-576	4.7	51
253	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3. <i>Arthritis and Rheumatology</i> , 2021 , 73, e60-e75	9.5	51
252	Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. <i>Journal of Rheumatology</i> , 2015 , 42, 504-12	4.1	50
251	The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 430-6	2.4	49
250	Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2016 , 43, 1997-2009	4.1	46
249	Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty. <i>Arthritis Care and Research</i> , 2017 , 69, 1845-1854	4.7	45
248	Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012 , 64, 1819-28	4.7	45
247	Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2011 , 13, R155	5.7	45

246	Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids. <i>Arthritis Care and Research</i> , 2019 , 71, 1249-1254	4.7	45
245	Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 341-7	2.4	44
244	Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program. <i>Arthritis Care and Research</i> , 2013 , 65, 1743-51	4.7	44
243	Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death. <i>Journal of the American Medical Directors Association</i> , 2010 , 11, 584-91	5.9	44
242	Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changes. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 858-64	6.3	42
241	Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials. <i>Medical Care</i> , 2011 , 49, 427-35	3.1	42
240	Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1456-64	9.5	41
239	Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort. <i>Arthritis Care and Research</i> , 2011 , 63, 1672-9	4.7	41
238	Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. <i>BMC Musculoskeletal Disorders</i> , 2016 , 17, 231	2.8	41
237	Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United States. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1733-1740	9.5	40
236	Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2012 , 64, 1480-9	4.7	39
235	Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. <i>BMC Cardiovascular Disorders</i> , 2017 , 17, 76	2.3	38
234	Management of osteoporosis among the elderly with other chronic medical conditions. <i>Drugs and Aging</i> , 2012 , 29, 549-64	4.7	38
233	The delivery of evidence-based preventive care for older Americans with arthritis. <i>Arthritis Research and Therapy</i> , 2010 , 12, R144	5.7	38
232	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2. <i>Arthritis and Rheumatology</i> , 2021 , 73, e30-e45	9.5	38
231	Wrist Fracture and Risk of Subsequent Fracture: Findings from the Women's Health Initiative Study. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 2086-95	6.3	37
230	Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. <i>Arthritis Care and Research</i> , 2012 , 64, 1282-91	4.7	37
229	Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. <i>RMD Open</i> , 2020 , 6,	5.9	36

228	Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example. <i>Medical Care</i> , 2008 , 46, 969-75	3.1	36
227	Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 285-291	2.4	36
226	Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 44, 381-8	5.3	35
225	The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 683-8	6.3	35
224	Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1012-1016	2.4	33
223	Tocilizumab and the Risk of Cardiovascular Disease: Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2019 , 71, 1004-1018	4.7	33
222	Osteoporosis medication adherence: physician perceptions vs. patientsPutilization. <i>Bone</i> , 2013 , 55, 1-6	4.7	32
221	What Proportion of Incident Radiographic Vertebral Fractures in Older Men Is Clinically Diagnosed and Vice Versa: A Prospective Study. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1500-3	6.3	31
220	Validation study of medicare claims to identify older US adults with CKD using the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. <i>American Journal of Kidney Diseases</i> , 2015 , 65, 249-58	7.4	31
219	Osteoporosis care in the United States after declines in reimbursements for DXA. <i>Journal of Clinical Densitometry</i> , 2010 , 13, 352-60	3.5	31
218	Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014. <i>Chest</i> , 2018 , 154, 1311-1320	5.3	31
217	Commentary: the five Ws of a Fracture Liaison Service: why, who, what, where, and how? In osteoporosis, we reap what we sow. <i>Current Osteoporosis Reports</i> , 2013 , 11, 365-8	5.4	30
216	Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. <i>Arthritis Care and Research</i> , 2012 , 64, 1054-60	4.7	30
215	Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial. <i>American Journal of Medicine</i> , 2019 , 132, 354-361	2.4	30
214	Association of intact parathyroid hormone levels with subsequent hip BMD loss: the Osteoporotic Fractures in Men (MrOS) Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 1937-44	5.6	29
213	Advancing the Science and Practice of Medication Adherence. <i>Journal of General Internal Medicine</i> , 2018 , 33, 216-222	4	29
212	Concerns, Healthcare Use, and Treatment Interruptions in Patients With Common Autoimmune Rheumatic Diseases During the COVID-19 Pandemic. <i>Journal of Rheumatology</i> , 2021 , 48, 603-607	4.1	29
211	Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry. <i>Chest</i> , 2017 , 152, 1120-1127	5.3	28

210	Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1881-1888	6.3	28
209	Vaccinations for rheumatoid arthritis. <i>Current Rheumatology Reports</i> , 2014 , 16, 431	4.9	28
208	Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States. <i>Arthritis Care and Research</i> , 2014 , 66, 1604-11	4.7	28
207	Bridging the osteoporosis quality chasm. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 3-7	6.3	28
206	Converting modified health assessment questionnaire (HAQ), multidimensional HAQ, and HAQII scores into original HAQ scores using models developed with a large cohort of rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2010 , 62, 1481-8	4.7	28
205	Incidence and prevalence of axial spondyloarthritis: methodologic challenges and gaps in the literature. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 263-274	2.2	28
204	Patient perspectives on achieving treat-to-target goals: a critical examination of patient-reported outcomes. <i>Arthritis Care and Research</i> , 2013 , 65, 1707-12	4.7	27
203	Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. <i>Arthritis Care and Research</i> , 2010 , 62, 101-7	4.7	27
202	Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis : A Cohort Study. <i>Annals of Internal Medicine</i> , 2020 , 173, 870-878	8	27
201	International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group. <i>Arthritis Care and Research</i> , 2019 , 71, 1556-1565	4.7	27
200	Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. <i>RMD Open</i> , 2019 , 5, e000942	5.9	26
199	Tumor necrosis factor inhibitors and infection complications. <i>Current Rheumatology Reports</i> , 2008 , 10, 383-9	4.9	26
198	Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 827-35	2.6	26
197	Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2015 , 67, 624-32	4.7	25
196	Increased pretreatment serum IFN- γ ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1757-62	2.4	25
195	Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. <i>Arthritis Research and Therapy</i> , 2018 , 20, 60	5.7	25
194	Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2015 , 21, 318-29	1.9	25
193	Predicting future response to certolizumab pegol in rheumatoid arthritis patients: features at 12 weeks associated with low disease activity at 1 year. <i>Arthritis Care and Research</i> , 2012 , 64, 658-67	4.7	25

192	Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 206-12	2.4	25
191	Routine Use of Quantitative Disease Activity Measurements among US Rheumatologists: Implications for Treat-to-target Management Strategies in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018 , 45, 40-44	4.1	25
190	Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2017 , 69, 313-322	4.7	24
189	Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH). <i>PLoS ONE</i> , 2015 , 10, e0135327	3.7	24
188	Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 390-400	2.2	24
187	Digital Interventions to Build a Patient Registry for Rheumatology Research. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 173-186	2.4	22
186	Herpes Zoster as a Risk Factor for Incident Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 2351-2358	2.2	22
185	Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication. <i>ClinicoEconomics and Outcomes Research</i> , 2016 , 8, 707-715	1.7	22
184	Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016 , 68, 1751-1757	4.7	21
183	Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis. <i>Journal of Medical Economics</i> , 2014 , 17, 555-66	2.4	21
182	Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2014 , 41, 1935-43	4.1	21
181	DXA Utilization Between 2006 and 2012 in Commercially Insured Younger Postmenopausal Women. <i>Journal of Clinical Densitometry</i> , 2015 , 18, 145-9	3.5	20
180	Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims. <i>Clinical Therapeutics</i> , 2014 , 36, 996-1004	3.5	20
179	Optimal use of available claims to identify a Medicare population free of coronary heart disease. <i>American Journal of Epidemiology</i> , 2015 , 182, 808-19	3.8	20
178	The effect of disease-modifying antirheumatic drugs on vaccine immunogenicity in adults. <i>Cleveland Clinic Journal of Medicine</i> , 2020 , 87, 695-703	2.8	20
177	Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care Setting 2016 , 20, 15-151		20
176	SARS CoV-2 infection among patients using immunomodulatory therapies. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 269-271	2.4	20
175	Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases. <i>Journal of Rheumatology</i> , 2017 , 44, 1083-1087	4.1	19

174	Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole. <i>Arthritis Research and Therapy</i> , 2019 , 21, 207	5.7	19
173	Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis. <i>BMC Cancer</i> , 2016 , 16, 381	4.8	19
172	"Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients". <i>BMC Musculoskeletal Disorders</i> , 2014 , 15, 113	2.8	19
171	Validity of Privacy-Protecting Analytical Methods That Use Only Aggregate-Level Information to Conduct Multivariable-Adjusted Analysis in Distributed Data Networks. <i>American Journal of Epidemiology</i> , 2019 , 188, 709-723	3.8	19
170	Patient Governance in a Patient-Powered Research Network for Adult Rheumatologic Conditions. <i>Medical Care</i> , 2018 , 56 Suppl 10 Suppl 1, S16-S21	3.1	19
169	A Randomized Trial Comparing the Specific Carbohydrate Diet to a Mediterranean Diet in Adults With Crohn's Disease. <i>Gastroenterology</i> , 2021 , 161, 837-852.e9	13.3	19
168	Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. <i>European Respiratory Journal</i> , 2019 , 54,	13.6	18
167	Osteoporotic fracture trends in a population of US managed care enrollees from 2007 to 2017. <i>Osteoporosis International</i> , 2020 , 31, 1299-1304	5.3	18
166	PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritis. <i>Journal of Patient-Reported Outcomes</i> , 2019 , 3, 14	2.6	18
165	A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1429-30	2.4	18
164	Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2017 , 69, 1526-1534	4.7	18
163	A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol. <i>Arthritis and Rheumatology</i> , 2015 , 67, 3104-12	9.5	18
162	Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2011 , 20, 1150-8	2.6	18
161	The Design and Validation of a New Algorithm to Identify Incident Fractures in Administrative Claims Data. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 1798-1807	6.3	17
160	Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 386-392	2.4	17
159	Physicians' Explanations for apparent gaps in the quality of rheumatology care: results from the US Medicare Physician Quality Reporting System. <i>Arthritis Care and Research</i> , 2013 , 65, 235-43	4.7	17
158	Injection-site burning and stinging in patients with rheumatoid arthritis using injectable biologics. <i>Current Medical Research and Opinion</i> , 2011 , 27, 71-8	2.5	17
157	Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study. <i>Hypertension</i> , 2020 , 75, 246-256	8.5	17

156	Perspectives of Rheumatoid Arthritis Patients on Electronic Communication and Patient-Reported Outcome Data Collection: A Qualitative Study. <i>Arthritis Care and Research</i> , 2019 , 71, 80-87	4.7	17
155	Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor. <i>Journal of Rheumatology</i> , 2019 , 46, 475-482	4.1	16
154	Herpes Zoster and the Risk of Stroke in Patients With Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2017 , 69, 439-446	9.5	16
153	Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients. <i>Seminars in Arthritis and Rheumatism</i> , 2013 , 43, 137-43	5.3	16
152	Prevention and treatment of glucocorticoid-induced osteoporosis. <i>Current Osteoporosis Reports</i> , 2007 , 5, 14-21	5.4	16
151	Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1255-1265	2.4	16
150	The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 310-319	2.6	15
149	A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 2019 , 37, 829-843	4.4	15
148	Prevalence of cardiovascular disease and major risk factors in patients with rheumatoid arthritis: a multinational cross-sectional study. <i>Clinical Rheumatology</i> , 2018 , 37, 2331-2340	3.9	15
147	Usability and Workflow Evaluation of "RhEumAtic Disease activityY" (READY). A Mobile Application for Rheumatology Patients and Providers. <i>Applied Clinical Informatics</i> , 2016 , 7, 1007-1024	3.1	15
146	Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine. <i>Arthritis Care and Research</i> , 2019 , 71, 1326-1335	4.7	15
145	Influence of obesity, age, and comorbidities on the multi-biomarker disease activity test in rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 47, 472-477	5.3	15
144	Studies with herpes zoster vaccines in immune compromised patients. <i>Expert Review of Vaccines</i> , 2017 , 16, 1217-1230	5.2	14
143	Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising. <i>Arthritis Research and Therapy</i> , 2017 , 19, 48	5.7	14
142	Does medication adherence itself confer fracture protection? An investigation of the healthy adherer effect in observational data. <i>Arthritis Care and Research</i> , 2012 , 64, 1855-63	4.7	14
141	Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy. <i>AIDS Research and Human Retroviruses</i> , 2006 , 22, 125-31	1.6	14
140	Swallowing difficulties from "DISH-phagia". <i>Journal of Rheumatology</i> , 2004 , 31, 2526-7	4.1	14
139	A randomized trial of a mailed intervention and self-scheduling to improve osteoporosis screening in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 2603-10	6.3	13

138	Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021 , 73, 1606-1616	4.7	12
137	Gastrointestinal Perforations with Biologics in Patients with Rheumatoid Arthritis: Implications for Clinicians. <i>Drug Safety</i> , 2018 , 41, 545-553	5.1	12
136	Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study. <i>Contemporary Clinical Trials</i> , 2016 , 50, 106-15	2.3	12
135	Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis. <i>Clinical Therapeutics</i> , 2017 , 39, 1680-1694.e2	3.5	12
134	Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2019 , 58, 874-883	3.9	12
133	Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission. <i>Arthritis and Rheumatology</i> , 2021 , 73, 759-768	9.5	12
132	Assessing a novel way to measure step count while walking using a custom mobile phone application. <i>PLoS ONE</i> , 2018 , 13, e0206828	3.7	12
131	Importance of Recent Fracture as Predictor of Imminent Fracture Risk. <i>Current Osteoporosis Reports</i> , 2018 , 16, 738-745	5.4	12
130	Data linkages between patient-powered research networks and health plans: a foundation for collaborative research. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019 , 26, 594-602	8.6	11
129	Agreement between Rheumatologist and Patient-reported Adherence to Methotrexate in a US Rheumatoid Arthritis Registry. <i>Journal of Rheumatology</i> , 2016 , 43, 1027-9	4.1	11
128	The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1447-57	3.8	11
127	Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. <i>Arthritis Research and Therapy</i> , 2015 , 17, 136	5.7	11
126	Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors. <i>Journal of Rheumatology</i> , 2014 , 41, 2078-84	4.1	11
125	Identifying newly approved medications in Medicare claims data: a case study using tocilizumab. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 1214-21	2.6	11
124	Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data. <i>Arthritis and Rheumatism</i> , 2011 , 63, 2203-8		11
123	Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 228-236	5.3	11
122	Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting. <i>RMD Open</i> , 2019 , 5, e001013	5.9	11
121	Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies. <i>Arthritis Research and Therapy</i> , 2021 , 23, 1	5.7	11

120	Is Rheumatoid Arthritis a Cardiovascular Risk-Equivalent to Diabetes Mellitus?. <i>Arthritis Care and Research</i> , 2018 , 70, 1694-1699	4.7	10
119	Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability. <i>PLoS ONE</i> , 2016 , 11, e0149781	3.7	10
118	Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies. <i>Current Medical Research and Opinion</i> , 2019 , 35, 1483-1493	2.5	10
117	Screening of Hyperlipidemia Among Patients With Rheumatoid Arthritis in the United States. <i>Arthritis Care and Research</i> , 2019 , 71, 1593-1599	4.7	10
116	Do Patients With Moderate or High Disease Activity Escalate Rheumatoid Arthritis Therapy According to Treat-to-Target Principles? Results From the Rheumatology Informatics System for Effectiveness Registry of the American College of Rheumatology. <i>Arthritis Care and Research</i> , 2020 , 72, 166-175	4.7	10
115	Republished: The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. <i>Postgraduate Medical Journal</i> , 2014 , 90, 722-9	3	9
114	Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients. <i>Pediatric Rheumatology</i> , 2016 , 14, 49	3.5	9
113	Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	9
112	A group randomized trial to improve safe use of nonsteroidal anti-inflammatory drugs. <i>American Journal of Managed Care</i> , 2005 , 11, 537-43	2.1	9
111	Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report. <i>Journal of Rheumatology</i> , 2017 , 44, 1894-1898	4.1	8
110	Pregnancy, Periods, and "The Pill": Exploring the Reproductive Experiences of Women with Inflammatory Arthritis. <i>ACR Open Rheumatology</i> , 2019 , 1, 125-132	3.5	8
109	Regional variation in the denial of reimbursement for bone mineral density testing among US Medicare beneficiaries. <i>Journal of Clinical Densitometry</i> , 2008 , 11, 568-74	3.5	8
108	Digital Tracking of Rheumatoid Arthritis Longitudinally (DIGITAL) Using Biosensor and Patient-Reported Outcome Data: Protocol for a Real-World Study. <i>JMIR Research Protocols</i> , 2019 , 8, e14665	2.65	8
107	Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower. <i>Arthritis Research and Therapy</i> , 2021 , 23, 53	5.7	8
106	Timing of Abatacept Before Elective Arthroplasty and Risk of Postoperative Outcomes. <i>Arthritis Care and Research</i> , 2019 , 71, 1224-1233	4.7	7
105	Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 573-580	2.4	7
104	Racial Disparities Exist in Outcomes After Major Fragility Fractures. <i>Journal of the American Geriatrics Society</i> , 2020 , 68, 1803-1810	5.6	7
103	A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial. <i>Arthritis Research and Therapy</i> , 2017 , 19, 215	5.7	7

102	Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment. <i>Arthritis Research and Therapy</i> , 2017 , 19, 276	5.7	7
101	Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept. <i>Patient</i> , 2018 , 11, 361-369	3.7	7
100	Improving osteoporosis care in high-risk home health patients through a high-intensity intervention. <i>Contemporary Clinical Trials</i> , 2012 , 33, 206-12	2.3	7
99	Validity of physician-reported hospitalized infections in a US arthritis registry. <i>Rheumatology</i> , 2009 , 48, 1269-72	3.9	7
98	Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 478-487	6.3	7
97	Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan Administrative Claims Database With Tofacitinib Trial Data. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1394-1408	4.5	7
96	Disruptions in Rheumatology Care and the Rise of Telehealth in Response to the COVID-19 Pandemic in a Community Practice-Based Network. <i>Arthritis Care and Research</i> , 2021 , 73, 1153-1161	4.7	7
95	Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection. <i>Journal of Rheumatology</i> , 2017 , 44, 565-570	4.1	6
94	An Internet-based Controlled Trial Aimed to Improve Osteoporosis Prevention among Chronic Glucocorticoid Users. <i>Journal of Rheumatology</i> , 2015 , 42, 1478-83	4.1	6
93	Use of ICD-10 diagnosis codes to identify seropositive and seronegative rheumatoid arthritis when lab results are not available. <i>Arthritis Research and Therapy</i> , 2020 , 22, 242	5.7	6
92	Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices. <i>ACR Open Rheumatology</i> , 2020 , 2, 79-83	3.5	6
91	Use of health plan combined with registry data to predict clinical trial recruitment. <i>Clinical Trials</i> , 2014 , 11, 96-101	2.2	6
90	Fractures and mortality in relation to different osteoporosis treatments. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 302-9	2.2	6
89	A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor- α Inhibitors: The NETWORK-004 Prospective Observational Study. <i>Rheumatology and Therapy</i> , 2021 , 8, 1159-1176	4.4	6
88	Improved Quality of Life With Anti-TNF Therapy Compared With Continued Corticosteroid Utilization in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 925-936	4.5	6
87	Assessing Rheumatoid Arthritis Disease Activity With Patient-Reported Outcomes Measurement Information System Measures Using Digital Technology. <i>Arthritis Care and Research</i> , 2020 , 72, 553-560	4.7	6
86	Gout is associated with an increased risk for incident heart failure among older adults: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study. <i>Arthritis Research and Therapy</i> , 2020 , 22, 86	5.7	6
85	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	6

84	American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4.. <i>Arthritis and Rheumatology</i> , 2022 , 74, e21-e36	9.5	6
83	Tools and Methods for Real-World Evidence Generation: Pragmatic Trials, Electronic Consent, and Data Linkages. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 275-289	2.4	5
82	The Validity of Claims-Based Algorithms to Identify Serious Hypersensitivity Reactions and Osteonecrosis of the Jaw. <i>PLoS ONE</i> , 2015 , 10, e0131601	3.7	5
81	Physical activity measured using wearable activity tracking devices associated with gout flares. <i>Arthritis Research and Therapy</i> , 2020 , 22, 181	5.7	5
80	Social Distancing, Health Care Disruptions, Telemedicine Use, and Treatment Interruption During the COVID-19 Pandemic in Patients With or Without Autoimmune Rheumatic Disease. <i>ACR Open Rheumatology</i> , 2021 , 3, 381-389	3.5	5
79	Contraception methods used by women with rheumatoid arthritis and psoriatic arthritis. <i>Clinical Rheumatology</i> , 2019 , 38, 1207-1212	3.9	5
78	Performance of Administrative Algorithms to Identify Interstitial Lung Disease in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020 , 72, 1392-1403	4.7	5
77	Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 757-769	2.6	5
76	Effects of the COVID-19 Pandemic on Patients Living With Vasculitis. <i>ACR Open Rheumatology</i> , 2021 , 3, 17-24	3.5	5
75	Which patient reported outcome domains are important to the rheumatologists while assessing patients with rheumatoid arthritis?. <i>BMC Rheumatology</i> , 2019 , 3, 36	2.9	4
74	Barriers to treatment optimization and achievement of patientsPgoals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry. <i>Arthritis Research and Therapy</i> , 2020 , 22, 4	5.7	4
73	Comparative safety of flavocoxid vs prescription NSAIDs among osteoarthritis patients. <i>Osteoarthritis and Cartilage</i> , 2020 , 28, 917-923	6.2	4
72	Assessing a novel way to measure three common rehabilitation outcome measures using a custom mobile phone application. <i>Gait and Posture</i> , 2019 , 73, 246-250	2.6	4
71	Evaluating and improving the quality of care in rheumatic disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2004 , 4, 429-39	2.2	4
70	Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long-Term Use of Glucocorticoids. <i>Arthritis Care and Research</i> , 2021 , 73, 1597-1605	4.7	4
69	Patient-Powered Research Networks of the Autoimmune Research Collaborative: Rationale, Capacity, and Future Directions. <i>Patient</i> , 2021 , 14, 699-710	3.7	4
68	Patient and Rheumatologist Perspectives Regarding Challenges to Achieving Optimal Disease Control in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020 , 72, 933-941	4.7	4
67	Benefits of Methotrexate Use on Cardiovascular Disease Risk Among Rheumatoid Arthritis Patients Initiating Biologic Disease-modifying Antirheumatic Drugs. <i>Journal of Rheumatology</i> , 2021 , 48, 804-812	4.1	4

66	Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1522-1529	2.4	4
65	Views of primary care physicians and rheumatologists regarding screening and treatment of hyperlipidemia among patients with rheumatoid arthritis. <i>BMC Rheumatology</i> , 2020 , 4, 14	2.9	3
64	Evaluation of a Methodologic Approach to Define an Inception Cohort of Rheumatoid Arthritis Patients Using Administrative Data. <i>Arthritis Care and Research</i> , 2018 , 70, 1541-1545	4.7	3
63	Development of algorithms for identifying fatal cardiovascular disease in Medicare claims. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 740-750	2.6	3
62	Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients. <i>Arthritis Research and Therapy</i> , 2018 , 20, 79	5.7	3
61	Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	3
60	Mapping from the International Classification of Diseases (ICD) 9th to 10th Revision for Research in Biologics and Biosimilars Using Administrative Healthcare Data. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 770-777	2.6	3
59	Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics. <i>Journal of Comparative Effectiveness Research</i> , 2020 , 9, 767-779	2.1	3
58	Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2020 , 22, 282	5.7	3
57	Racial and ethnic differences in medication use among beneficiaries of social security disability insurance with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 988-995	5.3	3
56	Meaningful Change Thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue and Pain Interference Scores in Patients With Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021 , 48, 1239-1242	4.1	3
55	Risk of Cardiovascular Outcomes among Psoriasis Patients Treated with Biologics and Other Systemic Agents. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2016 , 1, 128-137	1.1	3
54	Uptake and Clinical Utility of Multibiomarker Disease Activity Testing in the United States. <i>Journal of Rheumatology</i> , 2019 , 46, 237-244	4.1	3
53	Secular Trends in the Incidence of Hip Fracture Among Nursing Home Residents. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 1668-1675	6.3	3
52	Association of cardiovascular disease and traditional cardiovascular risk factors with the incidence of dementia among patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 292-298	5.3	3
51	Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data. <i>Rheumatology and Therapy</i> , 2021 , 8, 1661-1675	4.4	3
50	Improving medical record retrieval for validation studies in Medicare data. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 393-401	2.6	2
49	Identifying Minimal and Meaningful Change in PROMIS for Rheumatoid Arthritis: Use of Multiple Methods and Perspectives. <i>Arthritis Care and Research</i> , 2020 ,	4.7	2

48	Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021 , 73, 1114-1124	4.7	2
47	Harnessing health plan enrollee data to boost membership in patient-powered research networks. <i>BMC Health Services Research</i> , 2020 , 20, 462	2.9	2
46	Antiphospholipid Antibody Testing in a General Population Sample from the USA: An Administrative Database Study. <i>Scientific Reports</i> , 2020 , 10, 3102	4.9	2
45	Just the FRAX: Management of Glucocorticoid-Induced Osteoporosis. <i>Gastroenterology</i> , 2018 , 154, 748-750	5.3	2
44	An Observational Study of Cardiovascular Risks Associated with Rheumatoid Arthritis Therapies: A Comparison of Two Analytical Approaches 2018 , 22, 17-101		2
43	Medication interruptions and subsequent disease flares during the COVID-19 pandemic: a longitudinal online study of patients with rheumatic disease. <i>Arthritis Care and Research</i> , 2021 ,	4.7	2
42	Patient-Reported Nausea and Fatigue Related to Methotrexate: A Prospective, Self-Controlled Study in the ArthritisPower Registry. <i>Rheumatology and Therapy</i> , 2021 , 1	4.4	2
41	Trends of lymphoma incidence in US veterans with rheumatoid arthritis, 2002-2017. <i>RMD Open</i> , 2020 , 6,	5.9	2
40	Trends in Hospitalization Rates, Major Causes of Hospitalization, and In-Hospital Mortality in Rheumatoid Arthritis in the United States From 2000 to 2014. <i>ACR Open Rheumatology</i> , 2020 , 2, 715-724	3.5	2
39	Enhancing Patient Understanding of Medication Risks and Benefits. <i>Arthritis Care and Research</i> , 2020 ,	4.7	2
38	Tough Choices: Exploring Medication Decision-Making During Pregnancy and Lactation Among Women With Inflammatory Arthritis. <i>ACR Open Rheumatology</i> , 2021 , 3, 475-483	3.5	2
37	Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 285	5.7	2
36	Reply to Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 996-997	6.3	2
35	Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases. <i>Arthritis Care and Research</i> , 2021 , 73, 289-295	4.7	2
34	Defining and characterizing sustained remission in patients with rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018 , 37, 885-893	3.9	2
33	Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry. <i>Rheumatology International</i> , 2021 , 41, 1755-1761	3.6	2
32	Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. <i>Rheumatology and Therapy</i> , 2021 , 9, 243	4.4	2
31	Barriers and facilitators for screening and treatment of hyperlipidemia among patients with inflammatory arthritis. <i>BMC Rheumatology</i> , 2020 , 4, 26	2.9	1

30	Reply. <i>Arthritis and Rheumatology</i> , 2018 , 70, 795-796	9.5	1
29	Epidemiologic Research of Invasive Fungal Infections Using Large Healthcare Databases. <i>Current Fungal Infection Reports</i> , 2013 , 7, 320-325	1.4	1
28	Patient Perceptions and Preferences Regarding Telemedicine for Rheumatologic Care during the COVID-19 Pandemic.. <i>Arthritis Care and Research</i> , 2022 ,	4.7	1
27	COVID-19 Vaccine Uptake and Vaccine Hesitancy in Rheumatology Patients Receiving Immunomodulatory Therapies Treated In Community Practice Settings.. <i>Arthritis and Rheumatology</i> , 2022 ,	9.5	1
26	Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids. <i>PLoS ONE</i> , 2020 , 15, e0244239	3.7	1
25	Treatment Satisfaction and Decision-making from the Patient Perspective in Axial Spondyloarthritis: Real-World Data from a Descriptive Cross-sectional Survey Study from the ArthritisPower Registry. <i>ACR Open Rheumatology</i> , 2021 ,	3.5	1
24	Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients. <i>Scientific Reports</i> , 2020 , 10, 14607	4.9	1
23	Reply. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1769-1770	9.5	1
22	The promise and perils of "Big Data" focus on spondyloarthritis. <i>Current Opinion in Rheumatology</i> , 2019 , 31, 355-361	5.3	1
21	A Novel Method to Combine Assessment of Benefit and Harm: Outcome Measures in Rheumatology 3B Methodology Applied to Two Active Comparator Trials. <i>Arthritis Care and Research</i> , 2019 , 71, 319-322	4.7	1
20	Data-Driven Patient Clustering and Differential Clinical Outcomes in the Brigham and Women's Rheumatoid Arthritis Sequential Study Registry. <i>Arthritis Care and Research</i> , 2021 , 73, 471-480	4.7	1
19	Evaluation of the impact of age and adiposity on a multi-biomarker disease activity score before and after adjustment. <i>Clinical Rheumatology</i> , 2021 , 40, 2419-2426	3.9	1
18	Reply. <i>Arthritis and Rheumatology</i> , 2018 , 70, 320	9.5	1
17	The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy : A Randomized Controlled Trial. <i>Annals of Internal Medicine</i> , 2021 , 174, 1510-1518	8	1
16	Risk of Serious Infection With Low-dose Glucocorticoids in Patients With Rheumatoid Arthritis: An Instrumental Variable Analysis. <i>Epidemiology</i> , 2022 , 33, 65-74	3.1	1
15	Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor- α inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis.. <i>Expert Review of Molecular Diagnostics</i> , 2021 , 1-9	3.8	1
14	Evaluation of an Intervention to Support Patient-Rheumatologist Conversations About Escalating Treatment in Patients with Rheumatoid Arthritis: A Proof-of-Principle Study.. <i>ACR Open Rheumatology</i> , 2021 ,	3.5	1
13	Using negative control outcomes to assess the comparability of treatment groups among women with osteoporosis in the United States. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 854-863	2.6	0

12	Validation of an algorithm to identify incident interstitial lung disease in patients with rheumatoid arthritis.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 2	5.7	○
11	Higher Serum Urate Levels Are Associated With an Increased Risk for Sudden Cardiac Death. <i>Journal of Rheumatology</i> , 2021 , 48, 1745-1753	4.1	○
10	Response to: Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease? By Suyama and Okada. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e18	2.4	○
9	Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis. <i>International Immunopharmacology</i> , 2021 , 91, 107260	5.8	○
8	Prevalence of Renal Impairment in a US Commercially Insured Rheumatoid Arthritis Population: A Retrospective Analysis. <i>Rheumatology and Therapy</i> , 2021 , 8, 1383-1391	4.4	○
7	Development and validation of the Methotrexate Experience Questionnaire, a new methotrexate oral treatment adherence tool in rheumatoid arthritis. <i>Journal of Patient-Reported Outcomes</i> , 2021 , 5, 69	2.6	○
6	The Annual Diagnostic Prevalence of Ankylosing Spondylitis and Axial Spondyloarthritis in the United States Using Medicare and MarketScan Databases. <i>ACR Open Rheumatology</i> , 2021 , 3, 743-752	3.5	○
5	Protocol for the pilot randomized trial of the Cardiovascular Risk assessment for Rheumatoid Arthritis (CARE RA) intervention: a peer coach behavioral intervention.. <i>Pilot and Feasibility Studies</i> , 2022 , 8, 84	1.9	○
4	Reply. <i>Arthritis Care and Research</i> , 2020 , 72, 736-738	4.7	
3	Study of Biologics and Biosimilars 2019 , 561-580		
2	Reply. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1771-1772	9.5	
1	Patient Perspectives on Biologics for Axial Spondyloarthritis in a Cross-sectional Study in a Predominantly Female Population: Treatment Satisfaction, Wear-off Between Doses, and Use of Supplemental Medication.. <i>Rheumatology and Therapy</i> , 2021 , 9, 509	4.4	